Old Dog, New Tricks: Label Expansions Invigorate Diabetic Nephropathy Market
You may also be interested in...
Novo Nordisk announced another set of positive PIONEER trial data backing its oral GLP-1 receptor agonist semaglutide, this time showing superior reduction of blood sugar levels and weight in adults with type 2 diabetes compared with placebo.
In an exclusive interview, Alexion R&D head John Orloff takes In Vivo on a tour around the company’s rejuvenated pipeline and explains how the business is innovating to pre-empt the Soliris-shaped hole in its balance sheet.
Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.